Big changes at Novo Nordisk
Big changes at Novo Nordisk Danish giant Novo Nordisk is to stop small–molecule R&D activities. The company will instead focus on its protein–based pharmaceuticals. As a result, around 90 of Novo Nordisk’s 180 employees focused on this area are expected to be made redundant. Existing projects will be outlicensed.